JP2018506570A - ドライアイ疾患及び他の眼障害の治療のための方法及び組成物 - Google Patents

ドライアイ疾患及び他の眼障害の治療のための方法及び組成物 Download PDF

Info

Publication number
JP2018506570A
JP2018506570A JP2017545544A JP2017545544A JP2018506570A JP 2018506570 A JP2018506570 A JP 2018506570A JP 2017545544 A JP2017545544 A JP 2017545544A JP 2017545544 A JP2017545544 A JP 2017545544A JP 2018506570 A JP2018506570 A JP 2018506570A
Authority
JP
Japan
Prior art keywords
eye
dry eye
oil
ophthalmic
brimonidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017545544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506570A5 (enExample
Inventor
ジェイン，サンディープ
コンペラ，ウダイ，バスカル
ムスヌリ，シャンカル
Original Assignee
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ
ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ
オクジェン アイエヌシー．
オクジェン アイエヌシー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ, ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ, オクジェン アイエヌシー．, オクジェン アイエヌシー． filed Critical ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ
Publication of JP2018506570A publication Critical patent/JP2018506570A/ja
Publication of JP2018506570A5 publication Critical patent/JP2018506570A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017545544A 2015-02-24 2016-02-23 ドライアイ疾患及び他の眼障害の治療のための方法及び組成物 Pending JP2018506570A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562119857P 2015-02-24 2015-02-24
US62/119,857 2015-02-24
PCT/US2016/019207 WO2016138049A1 (en) 2015-02-24 2016-02-23 Methods and compositions for treating dry eye disease and other eye disorders

Publications (2)

Publication Number Publication Date
JP2018506570A true JP2018506570A (ja) 2018-03-08
JP2018506570A5 JP2018506570A5 (enExample) 2019-04-04

Family

ID=56692824

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545544A Pending JP2018506570A (ja) 2015-02-24 2016-02-23 ドライアイ疾患及び他の眼障害の治療のための方法及び組成物

Country Status (12)

Country Link
US (1) US9597328B2 (enExample)
EP (1) EP3261620B1 (enExample)
JP (1) JP2018506570A (enExample)
KR (1) KR20170132725A (enExample)
CN (1) CN107427459A (enExample)
AU (1) AU2016222902A1 (enExample)
BR (1) BR112017017448A2 (enExample)
CA (1) CA2976120A1 (enExample)
ES (1) ES2936394T3 (enExample)
MX (1) MX2017010544A (enExample)
RU (1) RU2691412C2 (enExample)
WO (1) WO2016138049A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019189721A1 (ja) * 2018-03-30 2019-10-03 千寿製薬株式会社 水性液剤
WO2019189720A1 (ja) * 2018-03-30 2019-10-03 千寿製薬株式会社 水性液剤
JP2023503524A (ja) * 2019-12-10 2023-01-30 アルコン インク． 生分解性ポリマーを有する溶解性ポリマー眼科用インサート

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US11478437B2 (en) * 2016-07-05 2022-10-25 Jenivision Inc. Formulations for hair growth
US10555947B2 (en) 2017-05-19 2020-02-11 Ocugen, Inc. Ophthalmic compositions and methods of use
SG11202004307UA (en) 2017-11-21 2020-06-29 Axerovision Inc Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
CN119174758A (zh) 2017-12-15 2024-12-24 塔苏斯制药有限公司 用于治疗睑炎的异恶唑啉驱虫剂制剂和方法
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
WO2020047197A1 (en) * 2018-08-29 2020-03-05 Ocugen, Inc. Ophthalmic compositions and methods of use
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
EP4192247A4 (en) * 2020-08-04 2025-01-08 Harrow IP, LLC Antibacterial compositions and methods for fabricating thereof
CN116710087A (zh) * 2020-11-23 2023-09-05 美国商业眼科医疗器械公司 用于治疗眼部病症的制剂和方法
US20220160668A1 (en) * 2020-11-23 2022-05-26 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye
CN115645356A (zh) * 2022-11-21 2023-01-31 山东诺明康药物研究院有限公司 一种酒石酸溴莫尼定原位凝胶及其制备方法和应用
WO2025174723A1 (en) * 2024-02-12 2025-08-21 Selagine Inc. Ophthalmic composition comprising cethromycin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534680A (ja) * 2005-04-04 2008-08-28 アドバンスト メディカル オプティクス， インコーポレーテッド ドライアイ緩和用のヒアルロン酸ナトリウムを含有する安定な眼科用水中油型エマルジョン
JP2010533225A (ja) * 2007-07-09 2010-10-21 インセプト エルエルシー ヒドロゲルポリマー組成物及び方法
JP2013534246A (ja) * 2010-08-16 2013-09-02 アラーガン インコーポレイテッド α−２Ｂアドレナリン受容体作動薬を用いて制御性Ｔ細胞を活性化する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK3412U (sk) * 2002-07-01 2003-01-09 Unimed Pharma Spol Sro Očná inštalácia so zlepšenou stabilitou účinnej látky na báze brimomidínu
US20040088199A1 (en) * 2002-10-31 2004-05-06 Childress Allen B. Method of forming a business rule
JP2007528897A (ja) * 2004-03-12 2007-10-18 メルビ ホールディングス， エルエルシー 眼表面用の潤滑剤
EP2070518A2 (en) * 2006-07-25 2009-06-17 Osmotica Corp. Ophthalmic solutions
CN101352441A (zh) * 2007-07-27 2009-01-28 肖正连 一种酒石酸溴莫尼定眼用即型凝胶
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
US20120082625A1 (en) * 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US20120093876A1 (en) * 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
BR112013025493A2 (pt) * 2011-04-05 2017-03-01 Optsolve Llp composição aquosa administrável de maneira tópica a um olho humano ou animal, método para tratar uma afecção que envolve deficiências em lágrimas naturais no olho humano ou animal, composição para aplicação tópica no tratamento de um distúrbio ou afecção ocular do olho humano ou animal, método para tratar um distúrbio ou afecção ocular do olho humano ou animal, composição para uso no tratamento de dor associada ao olho humano ou animal e método para alívio da dor no olho humano ou animal ou próximo ao mesmo
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008534680A (ja) * 2005-04-04 2008-08-28 アドバンスト メディカル オプティクス， インコーポレーテッド ドライアイ緩和用のヒアルロン酸ナトリウムを含有する安定な眼科用水中油型エマルジョン
JP2010533225A (ja) * 2007-07-09 2010-10-21 インセプト エルエルシー ヒドロゲルポリマー組成物及び方法
JP2013534246A (ja) * 2010-08-16 2013-09-02 アラーガン インコーポレイテッド α−２Ｂアドレナリン受容体作動薬を用いて制御性Ｔ細胞を活性化する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ファルマシア, vol. 46, no. 5, JPN6020004217, pages 452 - 453, ISSN: 0004364595 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019189721A1 (ja) * 2018-03-30 2019-10-03 千寿製薬株式会社 水性液剤
WO2019189720A1 (ja) * 2018-03-30 2019-10-03 千寿製薬株式会社 水性液剤
JP2019182849A (ja) * 2018-03-30 2019-10-24 千寿製薬株式会社 水性液剤
JP2019182848A (ja) * 2018-03-30 2019-10-24 千寿製薬株式会社 水性液剤
JP2020059761A (ja) * 2018-03-30 2020-04-16 千寿製薬株式会社 水性液剤
JP2020193233A (ja) * 2018-03-30 2020-12-03 千寿製薬株式会社 水性液剤
JP7438899B2 (ja) 2018-03-30 2024-02-27 千寿製薬株式会社 水性液剤
JP2024040421A (ja) * 2018-03-30 2024-03-25 千寿製薬株式会社 水性液剤
JP2023503524A (ja) * 2019-12-10 2023-01-30 アルコン インク． 生分解性ポリマーを有する溶解性ポリマー眼科用インサート
JP7406634B2 (ja) 2019-12-10 2023-12-27 アルコン インク． 生分解性ポリマーを有する溶解性ポリマー眼科用インサート

Also Published As

Publication number Publication date
EP3261620B1 (en) 2022-11-09
RU2017129247A3 (enExample) 2019-03-25
KR20170132725A (ko) 2017-12-04
RU2691412C2 (ru) 2019-06-13
WO2016138049A1 (en) 2016-09-01
RU2017129247A (ru) 2019-03-25
EP3261620A1 (en) 2018-01-03
ES2936394T3 (es) 2023-03-16
AU2016222902A1 (en) 2017-08-31
MX2017010544A (es) 2018-06-18
CN107427459A (zh) 2017-12-01
US20160243116A1 (en) 2016-08-25
EP3261620A4 (en) 2018-10-31
US9597328B2 (en) 2017-03-21
CA2976120A1 (en) 2016-09-01
BR112017017448A2 (pt) 2018-04-03

Similar Documents

Publication Publication Date Title
US9597328B2 (en) Methods and compositions for treating dry eye disease and other eye disorders
US10555947B2 (en) Ophthalmic compositions and methods of use
RU2639472C2 (ru) Офтальмическая композиция
JP5917490B2 (ja) 人工涙エマルション
US11260035B2 (en) Topical compositions and methods of use thereof
US20190008920A1 (en) Ophthalmic compositions and methods of use
US20250367297A1 (en) Ophthalmological compositions and methods of use thereof
CN111888326B (zh) 羟甲唑啉组合物和用于治疗眼障碍的方法
US10751337B2 (en) Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders
JP2019123714A (ja) 点眼剤
US20180221278A1 (en) Prsustained release opthalmic formuation and methods for using the same
US9877964B2 (en) Methods and compositions for treating dry eye disease and other eye disorders
CA3115664A1 (en) Ophthalmic compositions and methods of use
WO2023114986A1 (en) Ophthalmic pharmaceutical compositions and uses thereof
EP4268827A1 (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
US20230285286A1 (en) Drug vehicle compositions and methods of use thereof
US20220133626A1 (en) Topical compositions and methods of use thereof
HK40091801A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
CN116669705A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
HK40031931A (en) Oxymetazoline compositions and methods for treating ocular disorders
HK40097614A (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
US20250114375A1 (en) Pharmaceutical composition of lifitegrast and loteprednol etabonate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201013